Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of Illumina stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $196.80, for a total value of $393,600.00. Following the sale, the executive vice president now directly owns 37,941 shares in the company, valued at $7,466,788.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Marc Stapley also recently made the following trade(s):
- On Friday, July 14th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $173.56, for a total value of $347,120.00.
- On Monday, June 12th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $170.85, for a total value of $341,700.00.
Illumina, Inc. (NASDAQ:ILMN) traded down 0.98% during midday trading on Friday, hitting $189.32. The stock had a trading volume of 882,072 shares. The company has a market cap of $27.64 billion, a P/E ratio of 37.99 and a beta of 0.83. The firm’s 50-day moving average price is $181.43 and its 200 day moving average price is $174.88. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $199.95.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The business had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.86 EPS. On average, analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley Sells 2,000 Shares” was reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/insider-selling-illumina-inc-nasdaqilmn-evp-sells-2000-shares-of-stock-updated.html.
ILMN has been the topic of a number of recent research reports. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a research note on Wednesday, June 21st. Barclays PLC restated a “hold” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. BidaskClub downgraded Illumina from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 25th. Cowen and Company restated an “outperform” rating and set a $200.00 price objective on shares of Illumina in a research report on Wednesday, April 26th. Finally, Deutsche Bank AG restated a “hold” rating and set a $175.00 price objective (up from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $177.01.
Several hedge funds have recently bought and sold shares of the company. Advocacy Wealth Management Services LLC acquired a new stake in Illumina during the first quarter worth approximately $102,000. Advisory Services Network LLC acquired a new stake in Illumina during the first quarter worth approximately $117,000. Gemmer Asset Management LLC raised its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Penserra Capital Management LLC raised its stake in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the last quarter. Finally, Paradigm Asset Management Co. LLC raised its stake in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the last quarter. 93.91% of the stock is owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.